NeoGenomics names Warren Stone CEO effective Jan. 4, 2027
Bitget2026/10/05 20:07NeoGenomics named President and COO Warren Stone as CEO and a board member, effective Jan. 4, 2027. Stone, 54, previously held senior roles at Ortho Clinical Diagnostics and MilliporeSigma/Merck KGaA; he joined NeoGenomics in 2022. Board Chair Lynn Tetrault will step down as chair on Jan. 4, 2027, then exit the board at the 2027 annual meeting. Independent director Michael Kelly will become lead independent director on Jan. 4, 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610051605BIZWIRE_USPR_____20261005_BW134566) on October 05, 2026, and is solely responsible for the information contained therein.
- NeoGenomics named President and COO Warren Stone as CEO and a board member, effective Jan. 4, 2027.
- Stone, 54, previously held senior roles at Ortho Clinical Diagnostics and MilliporeSigma/Merck KGaA; he joined NeoGenomics in 2022.
- Board Chair Lynn Tetrault will step down as chair on Jan. 4, 2027, then exit the board at the 2027 annual meeting.
- Independent director Michael Kelly will become lead independent director on Jan. 4, 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Worst-Performing Altcoins This Week as BTC Battles to Hold $80K: Weekend Watch

Goldman Sachs dramatically lowers KOSPI target from 12,000 to 9,000 points, still insists there is 60% upside potential
Goldman Sachs strategists have lowered their 12-month target for South Korea's KOSPI Index from 12,000 points to 9,000 points, representing a 25% decrease. Earlier this year, Goldman had raised the target multiple times. The latest downgrade is due to mounting concerns in the market over artificial intelligence (AI) trading.

AI investment has not ended; wealth is simply being redistributed.
